

Notice reference number: TBA

Notice date: 19/02/2016

What's this about?

Effective date: 23/02/2016

- | | | | | | | |
|--|----------------------------------|-----------------------------------|-----------------------------|---|----------------------------|--|
| <input checked="" type="radio"/> ASX Trade | <input type="radio"/> ASX 24 | <input type="radio"/> ASX TECH | | | | |
| <input checked="" type="radio"/> Trading | <input type="radio"/> Clearing | <input type="radio"/> Settlement | <input type="radio"/> ALC | <input type="radio"/> ASX NET | | |
| <input type="radio"/> Operations | <input type="radio"/> Technology | <input type="radio"/> Market Data | <input type="radio"/> Rules | <input checked="" type="radio"/> Compliance | <input type="radio"/> Risk | <input checked="" type="radio"/> Other |

Title

MGC Pharmaceuticals Limited – Reinstatement to Official Quotation

Description

The securities of MGC Pharmaceuticals Limited (“the Company”) were suspended from Official Quotation on 13 November 2015.

The securities of the Company will be reinstated to Official Quotation from the commencement of trading on Tuesday, 23 February 2016, following the Company’s compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules.

Quoted Securities:	508,086,552 fully paid ordinary shares
ASX Code:	MXC
Time:	10:00 AM AEDT (7:00 AM WST)
Date:	Tuesday, 23 February 2016
ASX Trade Abbreviation:	MGC PHARMA
ISIN:	AU000000MXC6
Home Branch:	Perth
Industry Classification:	TBA
Registered Office:	Level 7, 1008 Hay Street, Perth, Western Australia 6000
Company Secretary:	Rachel Kerr
Share Registry:	Computershare Investor Services Pty Ltd Level 11, 172 St Georges Terrace PERTH WA 6000 Ph: +61 (0)8 9323 2000 Fax: +61 (0)8 9323 2033
Balance Date:	30 June
CHESS:	Participating. The Company will also operate an issuer sponsored sub-register
Place of Incorporation:	New South Wales

Dividend Policy:	See section 6.10 of the Company's prospectus dated 18 December 2015 ("Prospectus") for further details
Activities:	Cultivation of cannabis for medical and cosmetic products
Lead Manager	n/a
ASX Restricted Securities:	63,346,700 fully paid ordinary shares, classified by ASX as restricted securities and to be held in escrow for a period of 24 months from reinstatement to official quotation
	30,000,000 performance shares, classified by ASX as restricted securities and to be held in escrow for a period of 24 months from reinstatement to official quotation
	140,000,000 fully paid ordinary shares, classified by ASX as restricted securities and to be held in escrow for a period of 12 months from their date of issue, being until 15 February 2017
	70,000,000 performance shares, classified by ASX as restricted securities and to be held in escrow for a period of 12 months from their date of issue, being until 15 February 2017
ASX unquoted unrestricted securities:	4,000,000 unlisted options exercisable at \$0.20 on or before 30 June 2017
	1,000,000 unlisted options exercisable at \$0.30 on or before 23 January 2018
	500,000 unlisted options exercisable at \$0.35 on or before 23 January 2018
	500,000 unlisted options exercisable at \$0.40 on or before 23 January 2018
	36,250,000 unlisted options exercisable at \$0.025 on or before 30 June 2017
	11,250,000 unlisted options exercisable at \$0.04 on or before 30 June 2017

What do I need to do and by when?

Instructions

Please refer to the Prospectus and the Company's website for further information.

Need more information?

<u>Issued by</u>	<u>Contact Details</u>
Jeremy Newman	(08) 9224 0000